Who owns Recro Pharma?
- Ticker: SCTL
- CUSIP Number: 75629f109
Tip: Access positions for across all investors
Analyze quarterly positions in Recro Pharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Recro Pharma stock
Who bought or sold Recro Pharma this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| First Light Asset Management | 20M | $21M | 0% | Mar 2024 |
|
| Beryl Capital Management | 8.9M | $9.7M | 100% | Mar 2024 |
|
| AWM Investment Company | 7.9M | $8.5M | 9% | Mar 2024 |
|
| Vanguard Group | 3.1M | $3.3M | 0% | Mar 2024 |
|
| OV Management | 3.0M | $3.2M | 0% | Mar 2024 |
|
| Geode Capital Management | 1.0M | $1.1M | 28% | Mar 2024 |
|
| Trium Capital | 1.0M | $1.1M | 100% | Mar 2024 |
|
| Vazirani Asset Management | 750k | $810k | 100% | Mar 2024 |
|
| Skandinaviska Enskilda Banken AB | 717k | $775k | 100% | Mar 2024 |
|
| Crystalline Management | 519k | $560k | 100% | Mar 2024 |
|
| BlackRock | 492k | $531k | 81% | Mar 2024 |
|
| Clear Harbor Asset Management | 272k | $294k | -24% | Mar 2024 |
|
| FNY Investment Advisers | 250k | $270k | 100% | Mar 2024 |
|
| Samjo Management | 213k | $230k | -93% | Mar 2024 |
|
| Bridgeway Capital Management | 203k | $219k | -19% | Mar 2024 |
|
| Northern Trust | 200k | $217k | 45% | Mar 2024 |
|
| PenderFund Capital Management | 123k | $181k | 100% | Mar 2024 |
|
| Y-Intercept | 87k | $94k | 100% | Mar 2024 |
|
| Stephens | 75k | $81k | -76% | Mar 2024 |
|
| Global Retirement Partners | 72k | $77k | 27% | Mar 2024 |
|
| Citadel Advisors | 59k | $64k | -63% | Mar 2024 |
|
| Susquehanna International | 48k | $52k | 100% | Mar 2024 |
|
| Amplius Wealth Advisors | 48k | $52k | 0% | Mar 2024 |
|
| Morgan Stanley | 47k | $51k | 23585% | Mar 2024 |
|
| CSS | 46k | $50k | 100% | Mar 2024 |
|
| Millennium Management | 38k | $41k | -62% | Mar 2024 |
|
| Charles Schwab Investment Management | 37k | $40k | 0% | Mar 2024 |
|
| Bank of America Corporation | 32k | $35k | 0% | Mar 2024 |
|
| Two Sigma Securities | 28k | $30k | 100% | Mar 2024 |
|
| Virtu Financial | 25k | $27k | 100% | Mar 2024 |
|
| Titleist Asset Management | 23k | $25k | -89% | Mar 2024 |
|
| Two Sigma Investments | 20k | $21k | 100% | Mar 2024 |
|
| Wynnefield Capital | 13k | $14k | 0% | Mar 2024 |
|
| Commonwealth Equity Services | 12k | $13k | 0% | Mar 2024 |
|
| Dimension Capital Management Partners | 11k | $11k | 0% | Mar 2024 |
|
| Tower Research Capital | 10k | $11k | -53% | Mar 2024 |
|
| Qube Research & Technologies | 4.1k | $4.4k | 100% | Mar 2024 |
|
| Wells Fargo & Company | 954.00 | $1.0k | 1% | Mar 2024 |
|
| Capital Advisors | 557.00 | $999.982100 | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 502.00 | $542.009400 | 100% | Mar 2024 |
|
| Royal Bank of Canada | 402.00 | $0 | 14% | Mar 2024 |
|
| Bnp Paribas Arbitrage, Snc | 257.00 | $277.996900 | 0% | Mar 2024 |
|
Who sold out of Recro Pharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Royce & Associates | Dec 2023 | 3.3M | $1.2M |
| Caligan Partners | Dec 2023 | 1.7M | $592k |
| First Eagle Investment Management | Dec 2023 | 1.6M | $572k |
| Alyeska Investment Group | Dec 2023 | 1.6M | $560k |
| Nantahala Capital Management | Dec 2023 | 1.2M | $426k |
| HighMark Wealth Management | Dec 2023 | 485k | $170k |
| Bank of New York Mellon | Dec 2023 | 56k | $20k |
| Hrt Financial | Dec 2023 | 53k | $18k |
| Weaver Consulting Group | Dec 2023 | 20k | $7.0k |
| Sandy Spring Bank | Dec 2023 | 2.0k | $701.950800 |